1. Home
  2. TROO vs AGEN Comparison

TROO vs AGEN Comparison

Compare TROO & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TROOPS Inc.

TROO

TROOPS Inc.

N/A

Current Price

$2.15

Market Cap

287.1M

Sector

Technology

ML Signal

N/A

Logo Agenus Inc.

AGEN

Agenus Inc.

N/A

Current Price

$6.79

Market Cap

274.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TROO
AGEN
Founded
2005
1994
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Radio And Television Broadcasting And Communications Equipment
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
287.1M
274.8M
IPO Year
2008
1999

Fundamental Metrics

Financial Performance
Metric
TROO
AGEN
Price
$2.15
$6.79
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$14.50
AVG Volume (30 Days)
367.3K
996.7K
Earning Date
05-01-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
100.00
EPS
N/A
0.96
Revenue
N/A
$42,877,086.00
Revenue This Year
N/A
$107.63
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$7.15
Revenue Growth
N/A
89.95
52 Week Low
$1.02
$2.71
52 Week High
$5.28
$8.85

Technical Indicators

Market Signals
Indicator
TROO
AGEN
Relative Strength Index (RSI) 50.63 44.89
Support Level $1.79 $2.97
Resistance Level $2.27 $8.70
Average True Range (ATR) 0.20 0.53
MACD 0.01 -0.21
Stochastic Oscillator 51.61 12.37

Price Performance

Historical Comparison
TROO
AGEN

About TROO TROOPS Inc.

TROOPS Inc is a conglomerate group of various businesses with its headquarters based in Hong Kong. The group is principally engaged in money lending business in Hong Kong providing mortgage loans to high quality target borrowers, property investment to generate additional rental income and the development, operation and management of an online financial marketplace that provides one-stop financial technology solutions including API services by leveraging artificial intelligence, large data and blockchain, and cloud computing (SaaS). It derives revenue from Hong Kong and Australia. Majority of its revenue generates from domestic market.

About AGEN Agenus Inc.

Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.

Share on Social Networks: